Blends or Separate Vials: Fixed Ratios, Molar Arithmetic and Certificate Requirements

In a co-formulated vial the proportions are set during manufacture; in a multi-vial stack you set them yourself. Everything else that distinguishes the two formats — how the certificate reads, how concentrations are calculated, what a purity claim actually covers — follows from that one point. Choosing between them is therefore a design decision first and a purchasing decision second, and the commonest error in this whole category is treating a blended vial as though it contained a single molecule. This page sets out the three available formats, the ratio and molarity arithmetic that a blend forces on you, why a certificate for a multi-component product must look different from a single-peptide one, and which format fits which kind of study.

Three formats, not two

Compare the Wolverine blend with the Wolverine Stack and the distinction is immediately clear: the blend is one vial in which BPC-157 and TB-500 were freeze-dried together in a permanently fixed 1:1 mass ratio, while the stack consists of three individually sealed vials — BPC-157, TB-500 and GHK-Cu, whose proportions are entirely up to you.

Interpreting the label

A blend label states the total mass and, when the components are not present in equal amounts, the breakdown. "10 mg (5/5)" means two peptides at 5 mg each. A label showing only a single total — 80 mg, as on the four-component KLOW Blend — leaves it to the certificate to show how that 80 mg is apportioned, and in four-component products the split is usually uneven. If a blend's paperwork will not state the mass of each component, the product cannot be used for quantitative work.

Working out concentration per component

1. Start with the whole vial. A 10 mg (5/5) Wolverine vial dissolved in 2 mL is 5 mg/mL of peptide in total (10 ÷ 2).
2. Split it out. With 5 mg of each peptide in the vial, the solution contains 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500 — not 5 mg/mL of either one.
3. Per unit on the scale. A single U-100 unit is 0.01 mL and therefore contains 25 mcg of each peptide; drawing 0.1 mL gives 250 mcg of each, so 500 mcg of peptide altogether.
4. The separate-vial route to the same place. To reach 2.5 mg/mL of each from individual vials you would dissolve 5 mg of each peptide in 2 mL of diluent — two reconstitutions, two stoppers pierced for every transfer, but complete freedom to alter either concentration later.

The underlying mg/mL calculation is the same one any vial needs; peptide reconstitution math explained covers it.

Where equal mass misleads

Here is where even experienced researchers slip. Two components at the same mass concentration are at the same molar concentration only if they happen to weigh the same, which is rarely true.

• At 1,419.55 Da, BPC-157 at 2.5 mg/mL is 2.5 g/L ÷ 1,419.55 g/mol = 1.76 mM.
• At 889.02 Da, TB-500 at the same 2.5 mg/mL is 2.5 ÷ 889.02 = 2.81 mM.

So matching the masses delivers about 1.6 times more TB-500 molecules than BPC-157 molecules. Where stoichiometry or receptor occupancy is the question, the molar figure is the relevant one, and a blend with a fixed mass ratio gives you no way to adjust it. Studies needing equimolar arms must use individual vials.

Requirements for a blend certificate

For a single peptide, the certificate reports one HPLC purity value and one identity confirmation by mass spectrometry. A mixture cannot be described that way, so proper documentation has a different shape:

• A purity result for each component, obtained before the components were mixed. Each peptide ought to be synthesised, purified and released against its own certificate first. On a blend, "≥99% purity" normally means each input peptide met that limit — not that the mixture produces a single 99% peak.
• A chromatogram in which the components resolve. Peptides of differing hydrophobicity come off a reversed-phase column at different times, so a blend's trace should show the expected number of peaks in the expected area proportions. A single broad hump is a bad sign.
• The mass of each component in the vial, established either by weighing at the fill stage or by quantitative amino-acid analysis.
• Identity confirmed for each component: a mixture contains several molecular weights, and the MS data should account for every one of them.

How to read a peptide COA explains the general framework for interpreting these documents. If a supplier's blend certificate shows just one purity figure and one mass with no per-component breakdown, that document does not describe the product you are buying.

Matching format to purpose

Reach for a blend when

• Your protocol uses a ratio you have no plans to change — CJC-1295 + Ipamorelin is the obvious case, where two secretagogues hit different receptors on the same cell and the combination is the standard research configuration.
• The handling itself is a meaningful source of error: every reconstitution adds volumetric variance, a puncture and a contamination opportunity, and a four-component vial eliminates three of each.
• Cost per milligram of material matters and the supplied ratio is acceptable.

Reach for separate vials when

• You need to vary one component while holding the others constant — the essence of a concentration–response study.
• The comparison has to be equimolar rather than equal-mass.
• The components have very different stability. Methionine-containing sequences, copper peptides and disulfide-bonded peptides degrade at different rates, and once they are together in solution the entire vial is limited by the least robust of them.
• You need per-component traceability to a lot, whether for publication or for internal QC.
• The components need different pH conditions or different diluents in order to dissolve properly.

The NAD+ Longevity Stack typifies the second list: three individually sealed vials sold as a kit and reconstituted independently.

Frequent errors

• Reading the vial's total mass as if it were the mass of one component. An 80 mg four-component vial contains 80 mg of no single thing.
• Presuming an equal split when the label says nothing about one.
• Reporting a molar concentration for a blend without converting each component separately using its own molecular weight.
• Accepting a single purity value for a vial holding several peptides.
• Attempting to separate a blend to recover one peptide. After co-lyophilisation, separation requires preparative chromatography — if you need a single peptide, purchase it on its own from the lyophilized vial range.

Our full range of co-formulated vials and multi-vial kits is in peptide blends and stacks.